Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Fujian Shengdi Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Phase 3

Not yet recruiting

Conditions: Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

Interventions: Drug: HRS9531
Drug: Placebo

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 140

Registration Number: NCT06994650

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Phase 3

Not yet recruiting

Conditions: Bstructive Sleep Apnea (OSA) and Obesity

Interventions: Drug: HRS9531
Drug: HRS9531placebo

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 140

Registration Number: NCT06974851

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Phase 1

Not yet recruiting

Conditions: Obesity
Overweight

Interventions: Drug: HRS-5817 Injection
Drug: HRS-5817 Injection Placebo

First Posted Date: 2025-04-18

Last Posted Date: 2025-04-18

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT06934408

Locations: 🇨🇳
The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China

Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Weight Loss

Interventions: Drug: [14C]HRS9531

First Posted Date: 2025-03-03

Last Posted Date: 2025-07-04

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT06855147

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Efficacy and Safety of HRS9531 Tablet in Obese Subjects

Phase 2

Active, not recruiting

Conditions: Chronic Management of Body Weight

Interventions: Drug: HRS9531 Tablet
Drug: HRS9531 Tablet placebo

First Posted Date: 2025-02-24

Last Posted Date: 2025-06-12

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 166

Registration Number: NCT06841445

Locations: 🇨🇳
Nanjing Drum Tower hospital, Nanjing, Jiangsu, China

The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution

Phase 1

Completed

Conditions: Overweight/Obesity

Interventions: Drug: HRS9531 injection

First Posted Date: 2025-01-27

Last Posted Date: 2025-06-12

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06792955

Locations: 🇨🇳
Central Hospital Affiliated To Shandong First Medical University, Jinan, Shandong, China

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

Phase 1

Recruiting

Conditions: Overweight or Obesity

Interventions: Drug: HRS-4729 injection
Drug: HRS-4729 injection placebo
Drug: HRS9531 injection
Drug: HRS9531 injection placebo
Drug: Acetaminophen

First Posted Date: 2025-01-07

Last Posted Date: 2025-04-30

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 103

Registration Number: NCT06762600

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Dyslipidemia

Interventions: Drug: HRS-5632
Drug: Placebo

First Posted Date: 2024-12-13

Last Posted Date: 2025-04-08

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT06732154

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Acetaminophen
Drug: Metformin
Drug: Warfarin
Drug: Atorvastatin
Drug: Digoxin
Drug: HRS9531

First Posted Date: 2024-12-09

Last Posted Date: 2025-06-22

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 57

Registration Number: NCT06723691

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: HRS9531 injection
Drug: Metformin Hydrochloride tablets

First Posted Date: 2024-10-23

Last Posted Date: 2025-01-07

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT06654960

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy